Merck's stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. MRK, +2.42% surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytruda as monotherapy for the first-line treatment of metastatic non-small cell lung cancer.